Tango Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Tango Therapeutics R&D Spending Growth & History (TNGX)
Tango Therapeutics's r&d spending was $132.2M for fiscal 2025.
View full Tango Therapeutics company overviewTango Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $132.2M | −$11.8M | −8.17% |
| 2024 | 2024-12-31 | $143.9M | $28.7M | +24.93% |
| 2023 | 2023-12-31 | $115.2M | $9.3M | +8.77% |
| 2022 | 2022-12-31 | $105.9M | $28.3M | +36.41% |
| 2021 | 2021-12-31 | $77.6M | $27.6M | +55.30% |
| 2020 | 2020-12-31 | $50.0M | — | — |
Tango Therapeutics quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $37.2M | $4.4M | +13.39% |
| Q1 2026 | 2026-03-31 | $33.5M | −$2.9M | −7.98% |
| Q4 2025 | 2025-12-31 | $32.1M | −$1.8M | −5.41% |
| Q3 2025 | 2025-09-30 | $30.8M | −$2.4M | −7.36% |
| Q2 2025 | 2025-06-30 | $32.8M | −$5.8M | −15.13% |
| Q1 2025 | 2025-03-31 | $36.4M | −$1.6M | −4.26% |
| Q4 2024 | 2024-12-31 | $33.9M | $2.6M | +8.29% |
| Q3 2024 | 2024-09-30 | $33.3M | $6.1M | +22.52% |
| Q2 2024 | 2024-06-30 | $38.7M | $10.0M | +34.82% |
| Q1 2024 | 2024-03-31 | $38.1M | $10.0M | +35.76% |
| Q4 2023 | 2023-12-31 | $31.3M | $2.2M | +7.73% |
| Q3 2023 | 2023-09-30 | $27.1M | −$1.6M | −5.55% |
| Q2 2023 | 2023-06-30 | $28.7M | $4.9M | +20.77% |
| Q1 2023 | 2023-03-31 | $28.0M | $3.7M | +15.24% |
| Q4 2022 | 2022-12-31 | $29.1M | $7.5M | +34.47% |
| Q3 2022 | 2022-09-30 | $28.7M | $6.8M | +31.11% |
| Q2 2022 | 2022-06-30 | $23.7M | $4.7M | +24.44% |
| Q1 2022 | 2022-03-31 | $24.3M | $9.3M | +62.20% |
| Q4 2021 | 2021-12-31 | $21.6M | — | — |
| Q3 2021 | 2021-09-30 | $21.9M | $8.9M | +68.94% |
| Q2 2021 | 2021-06-30 | $19.1M | — | — |
| Q1 2021 | 2021-03-31 | $15.0M | — | — |
| Q3 2020 | 2020-09-30 | $13.0M | — | — |
Tango Therapeutics r&d spending trends
Over the last five fiscal years, Tango Therapeutics's r&d spending increased from $50.0M to $132.2M, a change of $82.2M. The latest reported quarter, Q2 2026, shows $37.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tango Therapeutics source filings ↗